REDWOOD CITY, Calif., Oct. 22, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced two presentations on its clinical stage hypoxia-activated prodrug, TH-302. The first is the Boston Biotech R&D Conference held today at the Harvard Medical School in Boston. The second is the European Organisation for Research and Treatment of Cancer (EORTC) conference, being held October 21-24, 2008 in Geneva.
